Inclusion Criteria:~* Ambulatory patients aged ≥ 50 years~* Diagnostic evidence of probable Alzheimer's disease
consistent with criteria from the National Institute of Neurological and Communicative Disorders and
Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) and the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)~* Confirmatory magnetic resonance imaging
(MRI) or computed tomographic (CT) scan within the prior 12 months.~* Mini-Mental State Examination (MMSE)
scores ≥ 3 and ≤ 14 at Screening (Visit 1) and Baseline (Visit 2)~* Ongoing daily acetylcholinesterase
inhibitor (AChEI) therapy at a stable dose for at least 3 months prior to Screening (Visit 1). It is preferred
that patients continue to receive the same AChEI therapy for the duration of the study.~
